Which has better earnings & valuation, ELOX or TTRX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eloxx Pharmaceuticals N/A N/A -$5.99M -$1.54 N/A Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A

Is ELOX or TTRX more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Turn Therapeutics N/A -230.84% -53.19%

Which has higher valuation & earnings, ELOX or NMRA?

Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eloxx Pharmaceuticals N/A N/A -$5.99M -$1.54 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A

Is ELOX or NMRA more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Neumora Therapeutics N/A -242.28% -131.32%

Is ZNTL or ELOX more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Eloxx Pharmaceuticals N/A N/A N/A

Do analysts prefer ELOX or ACB?

Eloxx Pharmaceuticals presently has a consensus target price of $41.50, indicating a potential upside of 176.67%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eloxx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Eloxx Pharmaceuticals (ELOX) Competitors

$15.00 +0.81 (+5.71%)

As of 04:00 PM Eastern

Compare

ELOX vs. AMRN, TTRX, NMRA, ZNTL, and ACB

Should you buy Eloxx Pharmaceuticals stock or one of its competitors? Eloxx Pharmaceuticals's main competitors and comparable companies include Amarin (AMRN), Turn Therapeutics (TTRX), Neumora Therapeutics (NMRA), Zentalis Pharmaceuticals (ZNTL), and Aurora Cannabis (ACB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eloxx Pharmaceuticals compare to Amarin?

Amarin (NASDAQ:AMRN) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Amarin had 3 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 3 mentions for Amarin and 0 mentions for Eloxx Pharmaceuticals. Amarin's average media sentiment score of 0.75 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Amarin is being referred to more favorably in the media.

Company	Overall Sentiment
Amarin	Positive
Eloxx Pharmaceuticals	Neutral

22.3% of Amarin shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Eloxx Pharmaceuticals has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.35	-$38.80M	-$0.99	N/A
Eloxx Pharmaceuticals	N/A	N/A	-$5.99M	-$1.54	N/A

Amarin presently has a consensus target price of $13.00, suggesting a potential downside of 4.62%. Eloxx Pharmaceuticals has a consensus target price of $41.50, suggesting a potential upside of 176.67%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Eloxx Pharmaceuticals' return on equity of 0.00% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Amarin has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its stock price is 186,326% less volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats Amarin on 10 of the 16 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Turn Therapeutics?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Eloxx Pharmaceuticals' return on equity of 0.00% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Turn Therapeutics	N/A	-230.84%	-53.19%

Turn Therapeutics is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$5.99M	-$1.54	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

In the previous week, Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Turn Therapeutics'average media sentiment score.

Company	Overall Sentiment
Eloxx Pharmaceuticals	Neutral
Turn Therapeutics	Neutral

Eloxx Pharmaceuticals presently has a consensus target price of $41.50, suggesting a potential upside of 176.67%. Turn Therapeutics has a consensus target price of $8.00, suggesting a potential downside of 18.37%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Eloxx Pharmaceuticals is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Eloxx Pharmaceuticals beats Turn Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Neumora Therapeutics?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$5.99M	-$1.54	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Eloxx Pharmaceuticals' return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Neumora Therapeutics	N/A	-242.28%	-131.32%

Eloxx Pharmaceuticals presently has a consensus target price of $41.50, indicating a potential upside of 176.67%. Neumora Therapeutics has a consensus target price of $6.57, indicating a potential upside of 401.64%. Given Neumora Therapeutics' higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Neumora Therapeutics had 2 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 2 mentions for Neumora Therapeutics and 0 mentions for Eloxx Pharmaceuticals. Neumora Therapeutics' average media sentiment score of 0.90 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eloxx Pharmaceuticals	Neutral
Neumora Therapeutics	Positive

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its stock price is 186,326% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market.

Summary

Neumora Therapeutics beats Eloxx Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Zentalis Pharmaceuticals currently has a consensus price target of $6.75, indicating a potential upside of 69.17%. Eloxx Pharmaceuticals has a consensus price target of $41.50, indicating a potential upside of 176.67%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Zentalis Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1862.26, suggesting that its stock price is 186,326% less volatile than the broader market.

Eloxx Pharmaceuticals' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Eloxx Pharmaceuticals	N/A	N/A	N/A

In the previous week, Zentalis Pharmaceuticals had 6 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 6 mentions for Zentalis Pharmaceuticals and 0 mentions for Eloxx Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.71 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Positive
Eloxx Pharmaceuticals	Neutral

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Eloxx Pharmaceuticals has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.24	-$137.06M	-$1.95	N/A
Eloxx Pharmaceuticals	N/A	N/A	-$5.99M	-$1.54	N/A

Summary

Eloxx Pharmaceuticals beats Zentalis Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Aurora Cannabis?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Eloxx Pharmaceuticals presently has a consensus target price of $41.50, indicating a potential upside of 176.67%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its share price is 186,326% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Eloxx Pharmaceuticals has higher earnings, but lower revenue than Aurora Cannabis. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$5.99M	-$1.54	N/A
Aurora Cannabis	$247.82M	1.03	-$88.13M	-$1.41	N/A

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Eloxx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Aurora Cannabis	-32.26%	4.37%	3.45%

In the previous week, Aurora Cannabis had 4 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 4 mentions for Aurora Cannabis and 0 mentions for Eloxx Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.00 beat Aurora Cannabis' score of -0.68 indicating that Eloxx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eloxx Pharmaceuticals	Neutral
Aurora Cannabis	Negative

Summary

Aurora Cannabis beats Eloxx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Eloxx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELOX vs. The Competition

Export

Metric	Eloxx Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$60.54M	$12.17B	$7.17B	$12.88B
Dividend Yield	N/A	2.59%	2.53%	8.57%
P/E Ratio	-9.74	787.21	272.99	25.40
Price / Sales	N/A	759.16	612.73	97.75
Price / Cash	N/A	94.80	77.82	52.27
Price / Book	1.30	12.46	12.85	6.17
Net Income	-$5.99M	$2.82B	$3.47B	$349.50M
7 Day Performance	-0.46%	3.80%	1.24%	-0.05%
1 Month Performance	-18.61%	6.77%	5.81%	0.80%
1 Year Performance	N/A	10.44%	25.75%	15.62%

Eloxx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELOX Eloxx Pharmaceuticals	2.3807 of 5 stars	$15.00 +5.7%	$41.50 +176.7%	N/A	$60.54M	N/A	N/A	N/A
AMRN Amarin	0.9161 of 5 stars	$14.38 +1.6%	$13.00 -9.6%	-8.8%	$298.89M	$213.65M	N/A	360	High Trading Volume
TTRX Turn Therapeutics	1.1265 of 5 stars	$9.63 -1.0%	$8.00 -16.9%	N/A	$289.84M	N/A	N/A	2
NMRA Neumora Therapeutics	1.9819 of 5 stars	$1.56 +4.0%	$6.57 +321.2%	-22.9%	$281.84M	N/A	N/A	108	Gap Down
ZNTL Zentalis Pharmaceuticals	2.7688 of 5 stars	$3.89 +0.3%	$6.75 +73.5%	+140.4%	$278.09M	$67.43M	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELOX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eloxx Pharmaceuticals (ELOX) Competitors

ELOX vs. AMRN, TTRX, NMRA, ZNTL, and ACB

How does Eloxx Pharmaceuticals compare to Amarin?

Summary

How does Eloxx Pharmaceuticals compare to Turn Therapeutics?

Summary

How does Eloxx Pharmaceuticals compare to Neumora Therapeutics?

Summary

How does Eloxx Pharmaceuticals compare to Zentalis Pharmaceuticals?

Summary

How does Eloxx Pharmaceuticals compare to Aurora Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX vs. The Competition

Eloxx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eloxx Pharmaceuticals (ELOX) Competitors

ELOX vs. AMRN, TTRX, NMRA, ZNTL, and ACB

How does Eloxx Pharmaceuticals compare to Amarin?

Does the media refer more to AMRN or ELOX?

Do institutionals and insiders hold more shares of AMRN or ELOX?

Which has better earnings & valuation, AMRN or ELOX?

Do analysts prefer AMRN or ELOX?

Is AMRN or ELOX more profitable?

Which has more volatility & risk, AMRN or ELOX?

Summary

How does Eloxx Pharmaceuticals compare to Turn Therapeutics?

Do institutionals & insiders hold more shares of ELOX or TTRX?

Is ELOX or TTRX more profitable?

Which has better earnings & valuation, ELOX or TTRX?

Does the media refer more to ELOX or TTRX?

Do analysts rate ELOX or TTRX?

Summary

How does Eloxx Pharmaceuticals compare to Neumora Therapeutics?

Which has higher valuation & earnings, ELOX or NMRA?

Is ELOX or NMRA more profitable?

Do analysts prefer ELOX or NMRA?

Do institutionals & insiders have more ownership in ELOX or NMRA?

Does the media prefer ELOX or NMRA?

Which has more risk and volatility, ELOX or NMRA?

Summary

How does Eloxx Pharmaceuticals compare to Zentalis Pharmaceuticals?

Do analysts rate ZNTL or ELOX?

Which has more risk & volatility, ZNTL or ELOX?

Is ZNTL or ELOX more profitable?

Does the media prefer ZNTL or ELOX?

Do institutionals and insiders have more ownership in ZNTL or ELOX?

Which has preferable earnings and valuation, ZNTL or ELOX?

Summary

How does Eloxx Pharmaceuticals compare to Aurora Cannabis?

Do analysts prefer ELOX or ACB?

Which has more risk and volatility, ELOX or ACB?

Do insiders and institutionals believe in ELOX or ACB?

Which has stronger earnings and valuation, ELOX or ACB?

Is ELOX or ACB more profitable?

Does the media refer more to ELOX or ACB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX vs. The Competition

Eloxx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools